APPLICATION OF TICAGRELOR OR CLOPIDOGREL BASED DUAL ANTIPLATELET THERAPY FOLLOWING A PHARMACOINVASIVE STRATEGY IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: INSIGHTS FROM THE VITAL HEART RESPONSE REGISTRY
2019
Ticagrelor (TIC) based dual antiplatelet therapy (DAPT) is standard of care for acute coronary syndromes (ACS) with the exception of fibrinolysis treated ST-segment elevation myocardial infarction (STEMI) patients where clopidogrel (CLOP) is recommended. Although comparable 30-day safety was shown
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI